Status:
UNKNOWN
Study of Seraprevir in Combination With Sofosbuvir in Chronic Genotype 2,3,6 Hepatitis C Virus Infection Patients
Lead Sponsor:
Ginkgopharma CO., LTD
Conditions:
Hepatitis C Virus Infection
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
This study was to assess the safety and efficacy of Seraprevir in combination with sofosbuvir in patients with Hepatitis C (HCV) genotype2,3,6. Efficacy was assessed by the rate of sustained viral res...
Eligibility Criteria
Inclusion
- Hepatitis C virus (HCV) genotype 2,3,6 infection (confirmed at screening). HCV RNA greater than 10,000 IU/mL at screening. Participant must be willing and able to comply with the protocol requirements. weight was more than 40 kg. age is between 18-75,either sex.
Exclusion
- Co-infection with hepatitis B virus or human immunodeficiency virus (HIV). Infection with HCV non-genotype 2,3,6,or Infection with mixed genotype,or Genotype cannot be confirmed.
- Medical history of major functional organ transplantation. Suffering from serious blood system disease(such us Thalassemia/Sickle Cell Anemia).
- Participation in a clinical study within 3 months prior to first dose
Key Trial Info
Start Date :
April 3 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 31 2020
Estimated Enrollment :
36 Patients enrolled
Trial Details
Trial ID
NCT04111367
Start Date
April 3 2019
End Date
August 31 2020
Last Update
October 1 2019
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Beijing Ditan Hospital,Capital Medical University
Beijing, Beijing Municipality, China
2
Liuzhou General Hospital
Liuchow, Guangxi, China
3
The first hospital of JILIN University.
Changchun, Jilin, China, 130000
4
The First Affiliated Hospital Of Guangxi Medical University
Guangxi, Nanning, China